FoundationOne CDx has been approved by the FDA as a companion diagnostic for patients with melanoma undergoing treatment with a BRAF inhibitor.
Pembrolizumab has been approved by the FDA as an adjuvant treatment for patients with stage IIB or IIC melanoma.
Phase 3 data indicated that the combination of nivolumab and ipilimumab followed by treatment with dabrafenib and trametinib, if necessary, resulted in greater overall survival at 2 years for patients with treatment-naïve BRAF-mutant metastatic melanoma.
Patients with melanoma, head and neck squamous cell carcinoma, and cervical cancer who had not previously received immunotherapy and were treated with lifileucel plus pembrolizumab experienced promising overall response rates compared favorably with historical data on pembrolizumab monotherapy.
Patients with melanoma who have asymptomatic brain metastases had long-lasting responses after being treated with first-line nivolumab and ipilimumab.
Lifileucel, a tumor infiltrating therapy, could be the best treatment for heavily pretreated patients with advanced melanoma, with investigators at Atlantic Health System examining this treatment modality in clinical trials.
UV1 has received fast track designation from the FDA for the use in unresectable or metastatic melanoma.
John Kirkwood, MD, PhD, gives his opinion on duration of treatment for patients with melanoma.
Dr John Kirkwood explores the idea of taking drug holidays during melanoma treatment and whether it is helpful or harmful.